Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer

被引:26
|
作者
Quenel-Tueux, Nathalie [1 ]
Debled, Marc [1 ]
Rudewicz, Justine [1 ,2 ,3 ,4 ,5 ]
MacGrogan, Gaetan [1 ,2 ,3 ]
Pulido, Marina [6 ,7 ]
Mauriac, Louis [1 ]
Dalenc, Florence [8 ]
Bachelot, Thomas [9 ]
Lortal, Barbara [1 ]
Breton-Callu, Christelle [1 ]
Madranges, Nicolas [1 ]
de lara, Christine Tunon [1 ]
Fournier, Marion [1 ]
Bonnefoi, Herve [1 ,2 ,3 ]
Soueidan, Hayssam [4 ]
Nikolski, Macha [3 ,4 ,5 ]
Gros, Audrey [1 ,2 ,3 ]
Daly, Catherine [10 ]
Wood, Henry [10 ]
Rabbitts, Pamela [10 ]
Iggo, Richard [1 ,2 ,3 ]
机构
[1] Inst Bergonie, Ctr Comprehens Canc, F-33000 Bordeaux, France
[2] INSERM, U916, F-33000 Bordeaux, France
[3] Univ Bordeaux, F-33608 Pessac, France
[4] Univ Bordeaux, Bordeaux Bioinformat Ctr, F-33076 Bordeaux, France
[5] CNRS, UMR5800, Bordeaux Comp Sci Lab, F-33405 Talence, France
[6] INSERM, Clin Invest Ctr, CIC1401, Epidemiol Unit, F-33076 Bordeaux, France
[7] Inst Bergonie, Clin & Epidemiol Res Unit, F-33076 Bordeaux, France
[8] Inst Claudius Regaud, IUCT Oncopole Toulouse, F-31059 Toulouse, France
[9] CLCC Lyon, F-69008 Lyon, France
[10] Univ Leeds, Leeds Inst Canc & Pathol, Leeds LS9 7TF, W Yorkshire, England
关键词
anastrozole; endocrine treatment; fulvestrant; hormone-receptor-positive cancer; large operable or locally advanced breast cancer; neo-adjuvant; NEOADJUVANT ENDOCRINE THERAPY; KI-67 LABELING INDEX; DOUBLE-BLIND; TAMOXIFEN; WOMEN; LETROZOLE; CHEMOTHERAPY; KI67;
D O I
10.1038/bjc.2015.247
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The aim of this study was to assess the efficacy of neoadjuvant anastrozole and fulvestrant treatment of large operable or locally advanced hormone-receptor-positive breast cancer not eligible for initial breast-conserving surgery, and to identify genomic changes occurring after treatment. Methods: One hundred and twenty post-menopausal patients were randomised to receive 1mg anastrozole (61 patients) or 500mg fulvestrant (59 patients) for 6 months. Genomic DNA copy number profiles were generated for a subgroup of 20 patients before and after treatment. Results: A total of 108 patients were evaluable for efficacy and 118 for toxicity. The objective response rate determined by clinical palpation was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 53.8% (95% CI = 39.5-67.8) in the fulvestrant arm. The breast-conserving surgery rate was 58.9% (95% CI = 45.0-71.9) in the anastrozole arm and 50.0% (95% CI = 35.8-64.2) in the fulvestrant arm. Pathological responses >50% occurred in 24 patients (42.9%) in the anastrozole arm and 13 (25.0%) in the fulvestrant arm. The Ki-67 score fell after treatment but there was no significant difference between the reduction in the two arms (anastrozole 16.7% (95% CI = 13.3-21.0) before, 3.2% (95% CI = 1.9-5.5) after, n = 43; fulvestrant 17.1% (95% CI = 13.1-22.5) before, 3.2% (95% CI = 1.8-5.7) after, n = 38) or between the reduction in Ki-67 in clinical responders and non-responders. Genomic analysis appeared to show a reduction of clonal diversity following treatment with selection of some clones with simpler copy number profiles. Conclusions: Both anastrozole and fulvestrant were effective and well-tolerated, enabling breast-conserving surgery in over 50% of patients. Clonal changes consistent with clonal selection by the treatment were seen in a subgroup of patients.
引用
收藏
页码:585 / 594
页数:10
相关论文
共 50 条
  • [31] Efficacy and safety of fulvestrant in postmenopausal patients with hormone receptor-positive advanced breast cancer: a systematic literature review and meta-analysis
    Jiayu Wang
    Binghe Xu
    Wenna Wang
    Xiaoyu Zhai
    Xuelian Chen
    Breast Cancer Research and Treatment, 2018, 171 : 535 - 544
  • [32] A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Patients with Advanced Breast Cancer After First-Line Chemotherapy
    Xu, Fei
    Zheng, Qiufan
    Xia, Wen
    Ouyang, Quchang
    Pang, Danmei
    Yuan, Zhongyu
    Shi, Yanxia
    Peng, Roujun
    Lu, Qianyi
    Wang, Shusen
    ONCOLOGIST, 2021, 26 (05): : E742 - E748
  • [33] Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
    Claudine Isaacs
    Pia Herbolsheimer
    Minetta C. Liu
    Mary Wilkinson
    Yvonne Ottaviano
    Gina G. Chung
    Robert Warren
    Jennifer Eng-Wong
    Philip Cohen
    Karen L. Smith
    Karen Creswell
    Antonella Novielli
    Rebecca Slack
    Breast Cancer Research and Treatment, 2011, 125 : 137 - 143
  • [34] Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer
    Isaacs, Claudine
    Herbolsheimer, Pia
    Liu, Minetta C.
    Wilkinson, Mary
    Ottaviano, Yvonne
    Chung, Gina G.
    Warren, Robert
    Eng-Wong, Jennifer
    Cohen, Philip
    Smith, Karen L.
    Creswell, Karen
    Novielli, Antonella
    Slack, Rebecca
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 125 (01) : 137 - 143
  • [35] Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naive Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
    Telford, Claire
    Bertranou, Evelina
    Large, Samuel
    Phelps, Hilary
    Ekman, Mattias
    Livings, Christopher
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 559 - 570
  • [36] Phase II Study Combining Pembrolizumab with Aromatase Inhibitor in Patients with Metastatic Hormone Receptor Positive Breast Cancer
    Ge, Xuan
    Yost, Susan E.
    Lee, Jin Sun
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Chung, Samuel
    Yeon, Christina
    Stewart, Daphne
    Li, Daneng
    Rajurkar, Swapnil
    Somlo, George
    Mortimer, Joanne
    Waisman, James
    Yuan, Yuan
    CANCERS, 2022, 14 (17)
  • [37] First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study
    Di Leo, Angelo
    Jerusalem, Guy
    Torres, Roberto
    Verhoeven, Didier
    Pendergrass, Kelly
    Malorni, Luca
    Lichfield, Jasmine
    Martin, Miguel
    BREAST, 2018, 38 : 144 - 149
  • [38] Hormonal Therapy Plus Bevacizumab in Postmenopausal Patients Who Have Hormone Receptor-Positive Metastatic Breast Cancer: A Phase II Trial of the Sarah Cannon Oncology Research Consortium
    Yardley, Denise A.
    Burris, Howard A., III
    Clark, Bobby L.
    Shipley, Dianna
    Rubin, Mark
    Barton, John, Jr.
    Arrowsmith, Edward
    Hainsworth, John D.
    CLINICAL BREAST CANCER, 2011, 11 (03) : 146 - 152
  • [39] A randomized phase II study of aromatase inhibitors plus metformin in pre-treated postmenopausal patients with hormone receptor positive metastatic breast cancer
    Zhao, Yannan
    Gong, Chengcheng
    Wang, Zhonghua
    Zhang, Jian
    Wang, Leiping
    Zhang, Sheng
    Cao, Jun
    Tao, Zhonghua
    Li, Ting
    Wang, Biyun
    Hu, Xichun
    ONCOTARGET, 2017, 8 (48) : 84224 - 84236
  • [40] Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer
    Dickler, Maura N.
    Saura, Cristina
    Richards, Donald A.
    Krop, Ian E.
    Cervantes, Andres
    Bedard, Philippe L.
    Patel, Manish R.
    Pusztai, Lajos
    Oliveira, Mafalda
    Cardenas, Alison K.
    Cui, Na
    Wilson, Timothy R.
    Stout, Thomas J.
    Wei, Michael C.
    Hsu, Jerry Y.
    Baselga, Jose
    CLINICAL CANCER RESEARCH, 2018, 24 (18) : 4380 - 4387